Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
127 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001084-CH
A Prospective Natural History Study of Lymphatic Anomalies
Participants currently recruited/enrolled
0-125 Years
NICHD
Protein
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
000908-DK
Peripheral Blood and Urine Immune Cell Phenotyping in Membranous Nephropathy using FACS and Single Cell RNA-seq
Participants currently recruited/enrolled
18-125 Years
NIDDK
Protein
000889-I
VRC 615: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB-0115-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
Participants currently recruited/enrolled
18-60 Years
NIAID
Protein
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Recruitment has not started
18-125 Years
NCI
Protein
000731-C
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-70 Years
NCI
Protein
000674-M
Assessment of [18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
Participants currently recruited/enrolled
18-99 Years
NIMH
Protein
000475-C
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Protein
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Protein
000235-CH
COLSIO Trial: Phase II Randomized, Controlled Trial of Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents with Obesity
Participants currently recruited/enrolled
12-125 Years
NICHD
Protein
000178-C
Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
000124-C
A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Recruitment has not started
2-21 Years
NCI
Protein
000081-C
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Completed Study; data analyses ongoing
2-125 Years
NCI
Protein
000062-C
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants with Pleural Mesotheliomas, or Pleural Effusions from Cancers Expressing Mesothelin
Participants currently recruited/enrolled
18-120 Years
NCI
Protein
22-I-0001
NADPH Oxidase Correction in mRNA transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Participants currently recruited/enrolled
18-75 Years
NIAID
Protein
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
21-H-0027
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens into the Human Lung
Participants currently recruited/enrolled
18-64 Years
NHLBI
Protein
20-M-0157
PET Imaging of Cyclooxygenase in Participants with Major Depressive Disorder (MDD)
Participants currently recruited/enrolled
18-70 Years
NIMH
Protein
20-I-0088
An Open-label Efficacy and Safety Study of Pozelimab in Patients with CD55 deficient Protein-losing Enteropathy (CHAPLE Disease)
Participants currently recruited/enrolled
3-125 Years
NIAID
Protein
20-H-0137
A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects with Stable Sickle Cell Disease
Completed Study; data analyses ongoing
18-46 Years
NHLBI
Protein
20-EI-0163
Oral Metformin for Treatment of ABCA4 Retinopathy
Participants currently recruited/enrolled
12-125 Years
NEI
Protein
20-C-0154
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
20-C-0106
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome
Participants currently recruited/enrolled
30-125 Years
NCI
Protein
20-C-0098
A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
20-C-0058
A Study of Front Line Ibrutinib for Newly Diagnosed Chronic Graft-Versus-Host Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
19-I-0015
Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
Participants currently recruited/enrolled
8-65 Years
NIAID
Protein
19-C-0128
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Protein
19-C-0042
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
18-N-0083
ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients
No longer recruiting/follow-up only
3-5 Years
NINDS
Protein
18-H-0146
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease
Participants currently recruited/enrolled
18-80 Years
NHLBI
Protein
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
18-C-0076
Bicalutamide With or Without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)
Completed Study; data analyses ongoing
18-85 Years
NCI
Protein
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Protein
18-C-0056
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
18-C-0026
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Participants currently recruited/enrolled
1-21 Years
NCI
Protein
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
17-N-0131
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Participants currently recruited/enrolled
18-125 Years
NINDS
Protein
17-CC-0148
Obtaining Samples from Human Subjects to Facilitate Basic, Translational and Clinical Research
Participants currently recruited/enrolled
18-125 Years
CC
Protein
17-C-0174
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
17-C-0164
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
17-C-0037
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
16-I-0078
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)
Participants currently recruited/enrolled
18-49 Years
NIAID
Protein
16-H-0063
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Completed Study; data analyses ongoing
1-70 Years
NHLBI
Protein
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
16-C-0094
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
15-N-0073
A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
Participants currently recruited/enrolled
3-99 Years
NINDS
Protein
15-I-0056
Collection of Plasma from Subjects that Recovered From or Were Vaccinated To Emerging Infectious Diseases
Enrolling by Invitation
18-70 Years
NIAID
Protein
15-EI-0038
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
No longer recruiting/follow-up only
18-125 Years
NEI
Protein
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
Protein
15-C-0086
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
Protein
15-C-0076
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Protein
14-HG-0071
Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation
Participants currently recruited/enrolled
1-80 Years
NHGRI
Protein
14-HG-0048
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)
Participants currently recruited/enrolled
21-125 Years
NHGRI
Protein
14-C-0156
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
14-C-0131
A Phase II, Open-Label Study in Patients With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
14-C-0036
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 I
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
14-C-0001
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
13-I-0082
Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases
Completed Study; data analyses ongoing
18-125 Years
NIAID
Protein
13-DK-0091
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Protein
13-C-0095
A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
13-C-0016
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
13-AG-0034
Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Completed Study; data analyses ongoing
55-125 Years
NIA
Protein
12-H-0150
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Participants currently recruited/enrolled
2-125 Years
NHLBI
Protein
12-EI-0203
Natural History of ABCA4-Related Retinopathies
No longer recruiting/follow-up only
12-125 Years
NEI
Protein
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Protein
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Protein
12-C-0079
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
11-I-0007
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency
Clinical hold/Recruitment or enrollment suspended
2-40 Years
NIAID
Protein
11-H-0134
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
No longer recruiting/follow-up only
2-125 Years
NHLBI
Protein
11-E-0072
Environmental Risk Factors for the Anti-Synthetase Syndrome
Participants currently recruited/enrolled
2-100 Years
NIEHS
Protein
11-C-0161
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
No longer recruiting/follow-up only
2-18 Years
NCI
Protein
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
10-E-0134
Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage
Completed Study; data analyses ongoing
18-100 Years
NIEHS
Protein
10-E-0129
Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin
Participants currently recruited/enrolled
18-125 Years
NIEHS
Protein
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
09-I-0184
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Participants currently recruited/enrolled
0-125 Years
NIAID
Protein
09-I-0126
Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes
Participants currently recruited/enrolled
2-90 Years
NIAID
Protein
09-H-0199
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Protein
09-DK-0223
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Participants currently recruited/enrolled
18-125 Years
NIDDK
Protein
09-C-0242
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Participants currently recruited/enrolled
4-125 Years
NCI
Protein
09-C-0139
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
09-C-0019
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
07-C-0107
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Flutamide, vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
06-M-0214
PET Measurement of Regional Rates of Cerebral Protein Synthesis in Subjects with Fragile X Syndrome
Completed Study; data analyses ongoing
18-24 Years
NIMH
Protein
06-EI-0068
The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
Completed Study; data analyses ongoing
18-125 Years
NEI
Protein
06-C-0150
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Protein
06-C-0014
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Participants currently recruited/enrolled
2-125 Years
NCI
Protein
05-CC-0041
Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets
Completed Study; data analyses ongoing
18-125 Years
CC
Protein
05-C-0252
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
04-DK-0021
Urinary Vitamin C Loss in Subjects with and without Diabetes
Participants currently recruited/enrolled
18-65 Years
NIDDK
Protein
04-CC-0119
Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage from Patients with Lung Infiltrates
Participants currently recruited/enrolled
3-99 Years
CC
Protein
04-C-0274
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
04-C-0238
A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
04-C-0232
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Completed Study; data analyses ongoing
18-125 Years
NCI
Protein
04-C-0200
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Participants currently recruited/enrolled
18-125 Years
NCI
Protein
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Protein
04-AR-0205
Progression of Spinal Fusion in Ankylosing Spondylitis
Completed Study; data analyses ongoing
18-125 Years
NIAMS
Protein
03-H-0280
Disease Pathogenesis and Natural History of Lipid Disorders
Participants currently recruited/enrolled
2-100 Years
NHLBI
Protein
02-I-0147
Genetic Studies of Chronic Active Epstein-Barr Virus Infection
Participants currently recruited/enrolled
1-125 Years
NIAID
Protein
02-DK-0022
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
Completed Study; data analyses ongoing
1-125 Years
NIDDK
Protein
02-CC-0266
Acute Cardiac Allograft Cellular Rejection and Cardiac Allograft Vasculopathy: Identification of Diagnostic Biomarkers and Target Pathways for Preventive Therapy
Completed Study; data analyses ongoing
18-125 Years
CC
Protein
02-C-0268
Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
Completed Study; data analyses ongoing
19-100 Years
NCI
Protein
02-C-0159
Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts
Participants currently recruited/enrolled
2-125 Years
NCI
Protein
01-CC-0045
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis
Participants currently recruited/enrolled
18-125 Years
CC
Protein
01-AR-0227
Studies of the Natural History of Rheumatic Disease in Minority Communities
Participants currently recruited/enrolled
18-100 Years
NIAMS
Protein
00-N-0140
A Prospective Natural History Study of VHL Patients with CNS Hemangioblastomas
No longer recruiting/follow-up only
8-75 Years
NINDS
Protein
00-HG-0153
Investigations into Chediak-Higashi Syndrome and Related Disorders
Participants currently recruited/enrolled
0-70 Years
NHGRI
Protein
00-H-0051
Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis
Participants currently recruited/enrolled
18-90 Years
NHLBI
Protein
00-DK-0107
Search for Novel Methods to Detect Acute Renal Failure
Participants currently recruited/enrolled
3-125 Years
NIDDK
Protein
00-CH-0136
A Trial of Pamidronate in Children with Osteogenesis Imperfecta
Completed Study; data analyses ongoing
2-17 Years
NICHD
Protein
95-H-0186
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
Participants currently recruited/enrolled
16-125 Years
NHLBI
Protein
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Participants currently recruited/enrolled
12-125 Years
NCI
Protein
76-H-0051
Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients
Completed Study; data analyses ongoing
18-80 Years
NHLBI
Protein